Weekly Buzz: EW, ABBV, MIRM Score FDA Wins, AZN, NVO Strike Deals; LLY, KOD Report Data

The biotech and pharmaceutical sector saw a fresh set of updates spanning regulatory milestones, clinical-study progress, strategic transactions and corporate activity. Developments covered therapeutic areas including oncology, rare diseases and cardiovascular disease, signaling continued pipeline advancement across the industry. The article does not provide specific financial results, trial data, transaction values or company-level price reactions.